ClinicalTrials.gg
CompletedNCT03578367Updated Apr 21, 2026Results posted

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

A Phase 2 interventional study of Asciminib add-on and Imatinib in CML, Chronic Myelogenous Leukemia and Leukemia, Myeloid Chronic, sponsored by Novartis Pharmaceuticals. Completed at 30 sites in 15 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 1 open to participants now, 5 under way, none of them phase 3. imatinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
26th of 83
104 · median 60
Started
2018
the only one that year
Phase 2
48 of 93
none open now
Registered
89th of 93
by date
Lead sponsor
15 of 93
Novartis Pharmaceuticals

Among the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 26th largest by enrollment of the 83 interventional ones that give a count, is the only one that started in 2018, is one of 48 in phase 2, and was the 89th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

1 of the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

To evaluate efficacy, safety and pharmacokinetic profile of asciminib 40mg+imatinib or asciminib 60mg+imatinib versus continued imatinib and versus nilotinib in pre-treated patients with Chronic Myeloid Leukemia in chronic phase (CML-CP). An asciminib single agent arm (80 mg daily) was added after the primary analysis to evaluate if asciminib alone could lead to MR4.5 patients in Imatinib for at least one year who have never achieved deep molecular response (DMR).

Read the detailed description

The study was a Phase 2, multi-center, open-label, randomized study of asciminib in two different doses (40 mg or 60 mg) in combination with imatinib 400 mg versus continued imatinib versus switch to nilotinib in participants with chronic myeloid leukemia in chronic phase (CML-CP) who had been previously treated with imatinib first line therapy for at least one year and had not achieved deep molecular response (DMR). Eligible participants were randomized 1:1:1:1 to receive asciminib 60 mg once daily (QD) as add-on therapy to imatinib 400 mg QD, or 40 mg QD as add-on therapy to imatinib 400 mg QD, or to continue imatinib 400 mg QD, or to switch to nilotinib 300 mg twice a day (BID). During the trial, there was no switch allowed. It was just at the moment of the randomization that the participants were selected to asciminib add-on arms or nilotinib.

Participants on the imatinib continuation arm who had not achieved MR4.5 at 48 weeks were allowed to cross-over ((CO) to receive the add-on treatment within 4 weeks after week 48 visit to receive the asciminib 60 mg combination add-on treatment, as this dose provided higher exposure. The cross-over was at the discretion of the investigator and the participant. Apart from a polymerase chain reaction (PCR) result of below MR4.5 at Week 48 visit, there were no other entry criteria for the cross-over part. Participants on nilotinib were not allowed to cross-over to receive the add-on treatment.

Participants on the study continued on the allocated treatment until treatment failure, intolerability, or for up to 96 weeks (in arms 1 to 4) after the last participant had received the first dose of treatment. After the last dose was received, every participant was followed up for safety for 30 days.

03

Conditions studied

  • CML
  • Chronic Myelogenous Leukemia
  • Leukemia, Myeloid Chronic
  • Hematologic Diseases

Keywords

  • CML
  • Chronic Myelogenous Leukemia
  • leukemia, myeloid chronic
  • Hematologic Diseases
  • Asciminib
  • ABL001
  • Imatinib
  • Nilotinib
  • deep molecular response
  • DMR
  • Ph+ CML
  • chronic phase
  • cancer of the white blood cells
  • tyrosine kinase inhibitor
  • leukemia, myeloid
  • leukemia
  • CML with Ph+
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Male or female patients ≥ 18 years of age with a confirmed diagnosis of CML-CP.
  • Minimum of one year (12 calendar months) treatment with imatinib for CML-CP (patients have to be on imatinib 400 mg QD at randomization and had no dose change in the past three months).

For Korea only:

(i) a minimum of one year (12 calendar months) of prior treatment with imatinib for patients with BCR::ABL1 levels > 0.1%, ≤ 1% IS at the time of randomization.

(ii) a minimum of two years (24 calendar months) of prior treatment with imatinib for patients with BCR::ABL 1 levels > 0.01%, ≤ 0.1% IS at the time of randomization.

  • BCR::ABL1 levels > 0.01% IS (International Scale) and ≤ 1% IS at the time of randomization as confirmed with a central assessment at screening; patients must not have achieved deep molecular response (MR4 IS) confirmed by 2 consecutive tests at any time during prior imatinib treatment. An isolated, single test result with BCR::ABL1 levels \< 0.01 % (MR4 IS) is allowed, however, it should not have been observed within the 9 months prior to randomization
  • Patient must meet the following laboratory values before randomization:
  • ≥ 1.5 x 10E9/L
  • ≥ 75 x 10E9/L
  • ≥ 9 g/dL
  • Serum creatinine \< 1.5 mg/dL
  • Total ≤ 1.5 x (Upper Limit of Normal) except for patients with Gilbert's syndrome who may only be included with total bilirubin ≤ 3.0 x ULN
  • (AST) ≤ 3.0 x ULN
  • Alanine transaminase (ALT) ≤ 3.0 x ULN
  • Alkaline phosphatase ≤ 2.5 x ULN
  • Serum lipase ≤ 1.5 x ULN
  • Participants must have the following laboratory values ≥ Lower Limit of Normal or corrected to within normal limits with supplements prior to randomization: potassium increase of up to 6.0 mmol/L is acceptable if associated with within normal limits ; calcium increase of up to 12.5 mg/dl or 3.1 mmol/L is acceptable if associated with creatinine clearance* within normal limits) ; magnesium increase up to 3.0 mg/dL or 1.23 mmol/L if associated with creatinine clearance within normal limits.

Key Exclusion Criteria:

  • Treatment failure according to European Leukemia Network (ELN) criteria 2013 during imatinib treatment.
  • Known second chronic phase of CML after previous progression to Accelerated Phase (AP)/Blast Crisis (BC).
  • Previous treatment with any tyrosine kinase inhibitors (TKIs) other than imatinib.
  • History or current diagnosis of abnormalities indicating significant risk or safety for participants participating in the study such as:
  • History of myocardial infarction, angina pectoris, coronary artery bypass graft within 6 months prior to randomization
  • Concomitant arrhythmias
  • Resting ≥ 450 msec (male) or ≥ 460 msec (female) prior to randomization
  • Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:

    • Risk factors for Torsades de Pointes
    • Concomitant medications with a "known" risk of Torsades de Pointes
    • inability to determine the QTcF interval 5. Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection, uncontrolled clinically significant hyperlipidemia and high serum amylase) 6. History of acute pancreatitis within 1 year prior to randomization or medical history of chronic pancreatitis; on-going acute liver disease or history of chronic liver disease 7. History of other active within 3 years prior to randomization with the exception of basal cell skin cancer, indolent prostate cancer and carcinoma in situ treated curatively.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Asciminib 60mg QD + Imatinib 400mg QD

    Asciminib 60 mg taken once daily in combination with Imatinib 400 mg taken once daily

    Drug: Asciminib add-on · Drug: Imatinib

  • Experimental
    Asciminib 40mg QD + Imatinib 400mg QD

    Asciminib 40 mg taken once daily in combination with Imatinib 400 mg taken once daily

    Drug: Asciminib add-on · Drug: Imatinib

  • Active comparator
    Imatinib 400mg QD

    Imatinib 400 mg taken once daily

    Drug: Imatinib

  • Active comparator
    Nilotinib 300mg BID

    Nilotinib 300 mg taken twice daily

    Drug: Nilotinib

  • Experimental
    Asciminib 80mg QD (ASAC)

    Asciminib 80 mg taken once daily

    Drug: Asciminib 80mg QD (asciminib single agent (ASAC))

Interventions

  • DrugAsciminib add-on

    Asciminib was supplied as 40 mg and 20 mg tablets and taken orally once daily.

    Also known as: ABL001 (asciminib)

  • Imatinib was supplied as 400 mg and 100 mg tablets and taken orally once daily.

    Also known as: STI571

  • Nilotinib was supplied as 150 mg and 200 mg hard gelatin capsules and taken orally twice daily.

    Also known as: AMN107

  • Asciminib was supplied as 40 mg and 20 mg tablets and taken orally once daily (in the fasted state) on a continuous schedule (QD).

    Also known as: ABL001

06

What researchers measure

Primary outcomes

  1. Molecular Response (MR)^4.5 Rate at 48 Weeks and Difference in Rate Between Asciminib + Imatinib and Imatinib Alone

    Percentage of participants still treated with the randomized treatment at 48 weeks and are in MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) at 48 weeks (± assessment window), among all participants in the asciminib add-on arms vs imatinib arm.

    Time frame: at Week 48

Secondary outcomes

  1. Rate of MR^4.5 at 48 Weeks (Asciminib add-on Arms vs Nilotinib)

    Percentage of participants in MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) at 48 weeks in asciminib add-on arms vs nilotinib arm.

    Time frame: at Week 48

  2. Rate of MR^4.5 by 48 Weeks (Randomized Arms)

    Best observed MR\^4.5 rate (BCR::ABL1 ratio of ≤ 0.0032%) up to 48 weeks, i.e. the percentage of participants who achieved MR 4.5 anytime up to 48 weeks.

    Time frame: by 48 weeks

  3. Rate of MR^4.5 at 96 Weeks (Randomized Arms) and Difference in Rate Between Asciminib + Imatinib and Nilotinib Alone

    Percentage of participants in MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) at 96 weeks in asciminib add-on arms vs nilotinib arm.

    Time frame: at Week 96

  4. Rate of MR^4.5 by 96 Weeks (Randomized Arms)

    Best observed MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) rate up to 96 weeks, i.e. the percentage of participants who achieved MR\^4.5 anytime up to 96 weeks.

    Time frame: by 96 weeks

  5. Sustained MR^4.5 From at 96 Weeks (Randomized Arms)

    Sustained MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) rate was defined as the percentage of participants who were in MR4.5 at 48 weeks and 96 weeks and who had no loss of MR4.5 in between those 2 time points.

    Time frame: at 96 weeks

  6. Time to MR^4.5 (Randomized Arms)

    Time to MR\^4.5 is the time from first dose to first MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) computed only for participants who achieved MR\^4.5 at least once before the cut-off date.

    Time frame: 96 weeks after the last participant received the first study dose

  7. Duration of MR^4.5 (Randomized Arms)

    Duration of MR\^4.5 was defined as the time from the first documented MR\^4.5 and the end date of MR\^4.5, i.e., the earliest date of loss of MR\^4.5 or CML-related death. Confirmed loss of MR\^4.5 is defined as an increase of the BCR::ABL1 ratio to \>0.0032% in two consecutive blood samples, by International Scale.

    Time frame: 96 weeks after the last participant received the first study dose

  8. Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - Cmax (Randomized Arms)

    The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1).

    Time frame: Week 2 Day 14: pre-dose (0h), 1h, 2h, 3hr 4h and 8h post-dose; Week 4 Day 28: pre-dose (0h) 2h, 3h, 4h post-dose

  9. Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - Tmax (Randomized Arms)

    The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time).

    Time frame: Week 2 Day 14: pre-dose (0h), 1h, 2h, 3hr 4h and 8h post-dose; Week 4 Day 28: pre-dose (0h) 2h, 3h, 4h post-dose

  10. Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - Cmin (Randomized Arms)

    Minimum drug plasma(serum/blood) concentration

    Time frame: Week 2 Day 14: pre-dose (0h), Week 4 Day 28: pre-dose (0h)

  11. Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - AUClast (Randomized Arms)

    The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1).

    Time frame: Week 2 Day 14: pre-dose (0h), 1h, 2h, 3hr 4h and 8h post-dose

  12. Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - AUCtau (Randomized Arms)

    The AUC calculated to the end of a dosing interval (tau) at steady-state

    Time frame: Week 2 Day 14: pre-dose (0h), 1h, 2h, 3hr 4h and 8h post-dose

  13. Molecular Response (MR) 4.5 Rate at 48 Weeks (Asciminib Single Agent Cohort (ASAC))

    Percentage of participants on asciminib 80 mg QD with MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) at 48 weeks.

    Time frame: at Week 48

  14. Time to MR^4.5 (ASAC)

    Time from first dose of asciminib 80 mg QD to first MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) computed only for participants who achieved MR\^4.5.

    Time frame: 48 weeks after the last enrolled participant (asciminib 80 mg cohort) received the first study dose

  15. Duration of MR^4.5 (ASAC)

    Time from first MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) until confirmed loss of MR\^4.5 or CML-related death.

    Time frame: 48 weeks after the last enrolled participant (asciminib 80 mg cohort) received the first study dose

  16. Pharmacokinetic Profile of Asciminib 80mg QD - Cmax (ASAC)

    The maximum (peak) observed plasma drug concentration after oral dose administration (mass x volume-1).

    Time frame: Week 2 Day 14: 0h (pre-dose), 1h, 2h, 3h, 4h, 8h post-dose; Week 4 Day 28: 0h (pre-dose), 2h, 3h, 4h post-dose

  17. Pharmacokinetic Profile of Asciminib 80mg QD - Tmax (ASAC)

    The time to reach maximum (Cmax) plasma drug concentration after oral dose administration (time).

    Time frame: Week 2 Day 14: 0h (pre-dose), 1h, 2h, 3h, 4h, 8h post-dose; Week 4 Day 28: 0h (pre-dose), 2h, 3h, 4h post-dose

  18. Pharmacokinetic Profile of Asciminib 80mg QD - Cmin (ASAC)

    Minimum drug plasma (serum/blood) concentration

    Time frame: Week 2 Day 14: 0h (pre-dose), Week 4 Day 28: 0h (pre-dose)

  19. Pharmacokinetic Profile of Asciminib 80mg QD - AUClast (ASAC)

    The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1).

    Time frame: Week 2 Day 14: 0h (pre-dose), 1h, 2h, 3h, 4h, 8h post-dose

  20. Pharmacokinetic Profile of Asciminib 80mg QD - AUCtau (ASAC)

    The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1)

    Time frame: Week 2 Day 14: 0h (pre-dose), 1h, 2h, 3h, 4h, 8h post-dose

07

Results

Posted Feb 14, 2025
Limitations and caveats
The use of zero (0) in the post-treatment period indicates adverse events were not collected.

Participant flow

All the participants were enrolled at 30 sites.

Participant flow — Overall Study
MilestoneAsciminib 40mg QD + Imatinib 400mg QDAsciminib 60mg QD + Imatinib 400mg QDImatinib 400mg QDNilotinib 300mg BIDAsciminib 80mg QD
Started2121212120
Treated2121202120
Discontinued from treatment3516101
Switched from imatinib to asciminib 60 mg combo014000
Completed181641119
Not completed3517101
Withdrew: Adverse event03071
Withdrew: Withdrawal by subject22130
Withdrew: Physician decision001400
Withdrew: Death10000
Withdrew: Not treated00100
Withdrew: Progressive disease00100

Outcome measures

PrimaryMolecular Response (MR)^4.5 Rate at 48 Weeks and Difference in Rate Between Asciminib + Imatinib and Imatinib Alone

Percentage of participants still treated with the randomized treatment at 48 weeks and are in MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) at 48 weeks (± assessment window), among all participants in the asciminib add-on arms vs imatinib arm.

Time frame:
at Week 48
Reported as:
Number · Percentage of participants
Molecular Response (MR)^4.5 Rate at 48 Weeks and Difference in Rate Between Asciminib + Imatinib and Imatinib Alone
Percentage of participantsAsciminib 40mg QD + Imatinib 400mg QDAsciminib 60mg QD + Imatinib 400mg QDImatinib 400mg QD
Molecular Response (MR)^4.5 Rate at 48 Weeks and Difference in Rate Between Asciminib + Imatinib and Imatinib Alone19.0 (6.8 to 38.4)28.6 (13.2 to 48.7)0.0 (0.0 to 13.3)
Statistical analysis
  • Asciminib 40mg QD + Imatinib 400mg QD vs Imatinib 400mg QD · Risk difference (rd): 19.05 · 90% CI 5.0 to 33.1
  • Asciminib 60mg QD + Imatinib 400mg QD vs Imatinib 400mg QD · Risk difference (rd): 28.57 · 90% CI 12.4 to 44.8
SecondaryRate of MR^4.5 at 48 Weeks (Asciminib add-on Arms vs Nilotinib)

Percentage of participants in MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) at 48 weeks in asciminib add-on arms vs nilotinib arm.

Time frame:
at Week 48
Reported as:
Number · Percentage of participants
Rate of MR^4.5 at 48 Weeks (Asciminib add-on Arms vs Nilotinib)
Percentage of participantsAsciminib 40mg QD + Imatinib 400mg QDAsciminib 60mg QD + Imatinib 400mg QDNilotinib 300mg BID
Rate of MR^4.5 at 48 Weeks (Asciminib add-on Arms vs Nilotinib)19.0 (6.8 to 38.4)28.6 (13.2 to 48.7)4.8 (0.2 to 20.7)
Statistical analysis
  • Asciminib 40mg QD + Imatinib 400mg QD vs Nilotinib 300mg BID · Risk difference (rd): 14.29 · 90% CI -1.7 to 30.3
  • Asciminib 60mg QD + Imatinib 400mg QD vs Nilotinib 300mg BID · Risk difference (rd): 23.81 · 90% CI 5.9 to 41.7
SecondaryRate of MR^4.5 by 48 Weeks (Randomized Arms)

Best observed MR\^4.5 rate (BCR::ABL1 ratio of ≤ 0.0032%) up to 48 weeks, i.e. the percentage of participants who achieved MR 4.5 anytime up to 48 weeks.

Time frame:
by 48 weeks
Reported as:
Number · Percentage of participants
Rate of MR^4.5 by 48 Weeks (Randomized Arms)
Percentage of participantsAsciminib 60mg QD + Imatinib 400mg QDAsciminib 40mg QD + Imatinib 400mg QDImatinib 400mg QDNilotinib 300mg BID
Rate of MR^4.5 by 48 Weeks (Randomized Arms)19.0 (6.8 to 38.4)28.6 (13.2 to 48.7)0 (0.0 to 13.3)14.3 (4.0 to 32.9)
SecondaryRate of MR^4.5 at 96 Weeks (Randomized Arms) and Difference in Rate Between Asciminib + Imatinib and Nilotinib Alone

Percentage of participants in MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) at 96 weeks in asciminib add-on arms vs nilotinib arm.

Time frame:
at Week 96
Reported as:
Number · Percentage of participants
Rate of MR^4.5 at 96 Weeks (Randomized Arms) and Difference in Rate Between Asciminib + Imatinib and Nilotinib Alone
Percentage of participantsAsciminib 40mg QD + Imatinib 400mg QDAsciminib 60mg QD + Imatinib 400mg QDNilotinib 300mg BID
Rate of MR^4.5 at 96 Weeks (Randomized Arms) and Difference in Rate Between Asciminib + Imatinib and Nilotinib Alone19.0 (6.8 to 38.4)19.0 (6.8 to 38.4)9.5 (1.7 to 27.1)
Statistical analysis
  • Asciminib 40mg QD + Imatinib 400mg QD vs Nilotinib 300mg BID · Risk difference (rd): 9.52 · 90% CI -8.1 to 27.1
  • Asciminib 60mg QD + Imatinib 400mg QD vs Nilotinib 300mg BID · Risk difference (rd): 9.52 · 90% CI -8.1 to 27.1
SecondaryRate of MR^4.5 by 96 Weeks (Randomized Arms)

Best observed MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) rate up to 96 weeks, i.e. the percentage of participants who achieved MR\^4.5 anytime up to 96 weeks.

Time frame:
by 96 weeks
Reported as:
Number · Percentage of participants
Rate of MR^4.5 by 96 Weeks (Randomized Arms)
Percentage of participantsAsciminib 60mg QD + Imatinib 400mg QDAsciminib 40mg QD + Imatinib 400mg QDImatinib 400mg QDNilotinib 300mg BID
Rate of MR^4.5 by 96 Weeks (Randomized Arms)28.6 (13.2 to 48.7)28.6 (13.2 to 48.7)9.5 (1.7 to 27.1)19.0 (6.8 to 38.4)
SecondarySustained MR^4.5 From at 96 Weeks (Randomized Arms)

Sustained MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) rate was defined as the percentage of participants who were in MR4.5 at 48 weeks and 96 weeks and who had no loss of MR4.5 in between those 2 time points.

Time frame:
at 96 weeks
Reported as:
Number · Percentage of participants
Sustained MR^4.5 From at 96 Weeks (Randomized Arms)
Percentage of participantsAsciminib 60mg QD + Imatinib 400mg QDAsciminib 40mg QD + Imatinib 400mg QDImatinib 400mg QDNilotinib 300mg BID
Sustained MR^4.5 From at 96 Weeks (Randomized Arms)14.3 (4.0 to 32.9)9.5 (1.7 to 27.1)0 (0.0 to 13.3)4.8 (0.2 to 20.7)
SecondaryTime to MR^4.5 (Randomized Arms)

Time to MR\^4.5 is the time from first dose to first MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) computed only for participants who achieved MR\^4.5 at least once before the cut-off date.

Time frame:
96 weeks after the last participant received the first study dose
Reported as:
Median · Weeks
Time to MR^4.5 (Randomized Arms)
WeeksAsciminib 60mg QD + Imatinib 400mg QDAsciminib 40mg QD + Imatinib 400mg QDImatinib 400mg QDNilotinib 300mg BID
Time to MR^4.5 (Randomized Arms)24.6 (8 to 120)12.4 (12 to 36)66.4 (61 to 72)36.3 (24 to 108)
SecondaryDuration of MR^4.5 (Randomized Arms)

Duration of MR\^4.5 was defined as the time from the first documented MR\^4.5 and the end date of MR\^4.5, i.e., the earliest date of loss of MR\^4.5 or CML-related death. Confirmed loss of MR\^4.5 is defined as an increase of the BCR::ABL1 ratio to \>0.0032% in two consecutive blood samples, by International Scale.

Time frame:
96 weeks after the last participant received the first study dose
Reported as:
Median · Weeks
Duration of MR^4.5 (Randomized Arms)
WeeksAsciminib 60mg QD + Imatinib 400mg QDAsciminib 40mg QD + Imatinib 400mg QDImatinib 400mg QDNilotinib 300mg BID
Duration of MR^4.5 (Randomized Arms)24.1 (11.9 to NA)NA (47.9 to NA)24.4 (23.6 to NA)NA (11.7 to NA)
SecondaryPharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - Cmax (Randomized Arms)

The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1).

Time frame:
Week 2 Day 14: pre-dose (0h), 1h, 2h, 3hr 4h and 8h post-dose; Week 4 Day 28: pre-dose (0h) 2h, 3h, 4h post-dose
Reported as:
Geometric mean · ng/mL
Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - Cmax (Randomized Arms)
ng/mLAsciminib 40mg QD + Imatinib 400mg QD (Asciminib)Asciminib 40mg QD + Imatinib 400mg QD (Imatinib)Asciminib 60mg QD + Imatinib 400mg QD (Asciminib)Asciminib 60mg QD + Imatinib 400mg QD (Imatinib)
Week 2 Day 14701.75 ± 32.162562.96 ± 29.491078.92 ± 34.482237.83 ± 30.42
Week 4 Day 28720.21 ± 25.532285.89 ± 29.281000.70 ± 33.502165.80 ± 41.41
SecondaryPharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - Tmax (Randomized Arms)

The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time).

Time frame:
Week 2 Day 14: pre-dose (0h), 1h, 2h, 3hr 4h and 8h post-dose; Week 4 Day 28: pre-dose (0h) 2h, 3h, 4h post-dose
Reported as:
Geometric mean · hour (hr)
Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - Tmax (Randomized Arms)
hour (hr)Asciminib 40mg QD + Imatinib 400mg QD (Asciminib)Asciminib 40mg QD + Imatinib 400mg QD (Imatinib)Asciminib 60mg QD + Imatinib 400mg QD (Asciminib)Asciminib 60mg QD + Imatinib 400mg QD (Imatinib)
Week 2 Day 142.76 ± 57.383.05 ± 36.312.30 ± 44.152.40 ± 59.04
Week 4 Day 282.67 ± 29.622.61 ± 29.972.61 ± 28.332.80 ± 25.99
SecondaryPharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - Cmin (Randomized Arms)

Minimum drug plasma(serum/blood) concentration

Time frame:
Week 2 Day 14: pre-dose (0h), Week 4 Day 28: pre-dose (0h)
Reported as:
Geometric mean · ng/mL
Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - Cmin (Randomized Arms)
ng/mLAsciminib 40mg QD + Imatinib 400mg QD (Asciminib)Asciminib 40mg QD + Imatinib 400mg QD (Imatinib)Asciminib 60mg QD + Imatinib 400mg QD (Asciminib)Asciminib 60mg QD + Imatinib 400mg QD (Imatinib)
Week 2 Day 14175 ± 41.21050 ± 39.1221 ± 62.7904 ± 62.4
Week 4 Day 28 (n = 20, 20, 18, 18)152 ± 58.5962 ± 39.3249 ± 52.6894 ± 39.8
SecondaryPharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - AUClast (Randomized Arms)

The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1).

Time frame:
Week 2 Day 14: pre-dose (0h), 1h, 2h, 3hr 4h and 8h post-dose
Reported as:
Geometric mean · hr*ng/mL
Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - AUClast (Randomized Arms)
hr*ng/mLAsciminib 40mg QD + Imatinib 400mg QD (Asciminib)Asciminib 40mg QD + Imatinib 400mg QD (Imatinib)Asciminib 60mg QD + Imatinib 400mg QD (Asciminib)Asciminib 60mg QD + Imatinib 400mg QD (Imatinib)
Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - AUClast (Randomized Arms)8683.46 ± 47.1937900.51 ± 47.4311889.74 ± 38.0734090.56 ± 44.54
SecondaryPharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - AUCtau (Randomized Arms)

The AUC calculated to the end of a dosing interval (tau) at steady-state

Time frame:
Week 2 Day 14: pre-dose (0h), 1h, 2h, 3hr 4h and 8h post-dose
Reported as:
Geometric mean · hr*ng/mL
Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - AUCtau (Randomized Arms)
hr*ng/mLAsciminib 40mg QD + Imatinib 400mg QD (Asciminib)Asciminib 40mg QD + Imatinib 400mg QD (Imatinib)Asciminib 60mg QD + Imatinib 400mg QD (Asciminib)Asciminib 60mg QD + Imatinib 400mg QD (Imatinib)
Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - AUCtau (Randomized Arms)9137.59 ± 37.9043794.83 ± 23.9312315.06 ± 39.4537440.73 ± 11.13
SecondaryMolecular Response (MR) 4.5 Rate at 48 Weeks (Asciminib Single Agent Cohort (ASAC))

Percentage of participants on asciminib 80 mg QD with MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) at 48 weeks.

Time frame:
at Week 48
Reported as:
Number · Percentage of participants
Molecular Response (MR) 4.5 Rate at 48 Weeks (Asciminib Single Agent Cohort (ASAC))
Percentage of participantsAsciminib 80mg QD
Molecular Response (MR) 4.5 Rate at 48 Weeks (Asciminib Single Agent Cohort (ASAC))35.0 (17.7 to 55.8)
SecondaryTime to MR^4.5 (ASAC)

Time from first dose of asciminib 80 mg QD to first MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) computed only for participants who achieved MR\^4.5.

Time frame:
48 weeks after the last enrolled participant (asciminib 80 mg cohort) received the first study dose
Reported as:
Median · Weeks
Time to MR^4.5 (ASAC)
WeeksAsciminib 80mg QD
Time to MR^4.5 (ASAC)24.3 (8 to 61)
SecondaryDuration of MR^4.5 (ASAC)

Time from first MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) until confirmed loss of MR\^4.5 or CML-related death.

Time frame:
48 weeks after the last enrolled participant (asciminib 80 mg cohort) received the first study dose
Reported as:
Median · Weeks
Duration of MR^4.5 (ASAC)
WeeksAsciminib 80mg QD
Duration of MR^4.5 (ASAC)24.1 (0 to 76)
SecondaryPharmacokinetic Profile of Asciminib 80mg QD - Cmax (ASAC)

The maximum (peak) observed plasma drug concentration after oral dose administration (mass x volume-1).

Time frame:
Week 2 Day 14: 0h (pre-dose), 1h, 2h, 3h, 4h, 8h post-dose; Week 4 Day 28: 0h (pre-dose), 2h, 3h, 4h post-dose
Reported as:
Geometric mean · ng/mL
Pharmacokinetic Profile of Asciminib 80mg QD - Cmax (ASAC)
ng/mLAsciminib 80mg QD
Week 2 Day 141319.32 ± 39.70
Week 4 Day 281250.01 ± 47.95
SecondaryPharmacokinetic Profile of Asciminib 80mg QD - Tmax (ASAC)

The time to reach maximum (Cmax) plasma drug concentration after oral dose administration (time).

Time frame:
Week 2 Day 14: 0h (pre-dose), 1h, 2h, 3h, 4h, 8h post-dose; Week 4 Day 28: 0h (pre-dose), 2h, 3h, 4h post-dose
Reported as:
Geometric mean · hour (hr)
Pharmacokinetic Profile of Asciminib 80mg QD - Tmax (ASAC)
hour (hr)Asciminib 80mg QD
Week 2 Day 141.93 ± 89.09
Week 4 Day 282.22 ± 24.38
SecondaryPharmacokinetic Profile of Asciminib 80mg QD - Cmin (ASAC)

Minimum drug plasma (serum/blood) concentration

Time frame:
Week 2 Day 14: 0h (pre-dose), Week 4 Day 28: 0h (pre-dose)
Reported as:
Geometric mean · ng/mL
Pharmacokinetic Profile of Asciminib 80mg QD - Cmin (ASAC)
ng/mLAsciminib 80mg QD
Week 2 Day 14169 ± 53.1
Week 4 Day 28 (n = 18)171 ± 52.1
SecondaryPharmacokinetic Profile of Asciminib 80mg QD - AUClast (ASAC)

The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1).

Time frame:
Week 2 Day 14: 0h (pre-dose), 1h, 2h, 3h, 4h, 8h post-dose
Reported as:
Geometric mean · hr*ng/mL
Pharmacokinetic Profile of Asciminib 80mg QD - AUClast (ASAC)
hr*ng/mLAsciminib 80mg QD
Pharmacokinetic Profile of Asciminib 80mg QD - AUClast (ASAC)13363.35 ± 48.33
SecondaryPharmacokinetic Profile of Asciminib 80mg QD - AUCtau (ASAC)

The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1)

Time frame:
Week 2 Day 14: 0h (pre-dose), 1h, 2h, 3h, 4h, 8h post-dose
Reported as:
Geometric mean · hr*ng/mL
Pharmacokinetic Profile of Asciminib 80mg QD - AUCtau (ASAC)
hr*ng/mLAsciminib 80mg QD
Pharmacokinetic Profile of Asciminib 80mg QD - AUCtau (ASAC)13725.57 ± 47.31

Adverse events

Collected over From first dose of study treatment to 30 days after last dose of study treatment for a minimum of 48 weeks and a maximum of 196 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
On-treatment Period Asciminib 40 mg + Imatinib1/21 (4.8%)3/21 (14.3%)20/21 (95.2%)
On-treatment Period Asciminib 60 mg + Imatinib0/21 (0%)4/21 (19%)18/21 (85.7%)
On-treatment Period Imatinib0/20 (0%)1/20 (5%)13/20 (65%)
On-treatment Period Nilotinib0/21 (0%)5/21 (23.8%)21/21 (100%)
On-treatment Period Asciminib 80 mg0/20 (0%)2/20 (10%)18/20 (90%)
On-treatment Period Switched From Imatinib to Asciminib 60 mg Combo0/14 (0%)1/14 (7.1%)10/14 (71.4%)
Post-treatment Period Asciminib 40 mg + Imatinib0/18 (0%)0/18 (0%)0/18 (0%)
Post-treatment Period Asciminib 60 mg + Imatinib0/18 (0%)0/18 (0%)0/18 (0%)
Post-treatment Period Imatinib0/19 (0%)0/19 (0%)0/19 (0%)
Post-treatment Period Nilotinib0/19 (0%)0/19 (0%)0/19 (0%)
Post-treatment Period Asciminib 80 mg0/20 (0%)0/20 (0%)0/20 (0%)
Post-treatment Period Switched From Imatinib to Asciminib 60 mg Combo0/14 (0%)0/14 (0%)0/14 (0%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventOn-treatment Period Asciminib 40 mg + ImatinibOn-treatment Period Asciminib 60 mg + ImatinibOn-treatment Period ImatinibOn-treatment Period NilotinibOn-treatment Period Asciminib 80 mgOn-treatment Period Switched From Imatinib to Asciminib 60 mg ComboPost-treatment Period Asciminib 40 mg + ImatinibPost-treatment Period Asciminib 60 mg + ImatinibPost-treatment Period ImatinibPost-treatment Period NilotinibPost-treatment Period Asciminib 80 mgPost-treatment Period Switched From Imatinib to Asciminib 60 mg Combo
Prostatic adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/210/210/200/210/201/14——————
Oedematous pancreatitisGastrointestinal disorders0/210/210/200/211/200/14——————
Abscess intestinalInfections and infestations0/210/211/200/210/200/14——————
Diverticulitis intestinal perforatedInfections and infestations0/210/211/200/210/200/14——————
Urinary tract infectionInfections and infestations1/210/210/200/211/200/14——————
Cardiac arrestCardiac disorders1/210/210/200/210/200/14——————
Appendiceal mucocoeleGastrointestinal disorders0/211/210/200/210/200/14——————
IleusGastrointestinal disorders0/210/210/201/210/200/14——————
PancreatitisGastrointestinal disorders0/211/210/200/210/200/14——————
Pancreatitis acuteGastrointestinal disorders0/210/210/201/210/200/14——————
Most frequent other events
Showing 10 of 68
Most frequent other events
EventOn-treatment Period Asciminib 40 mg + ImatinibOn-treatment Period Asciminib 60 mg + ImatinibOn-treatment Period ImatinibOn-treatment Period NilotinibOn-treatment Period Asciminib 80 mgOn-treatment Period Switched From Imatinib to Asciminib 60 mg ComboPost-treatment Period Asciminib 40 mg + ImatinibPost-treatment Period Asciminib 60 mg + ImatinibPost-treatment Period ImatinibPost-treatment Period NilotinibPost-treatment Period Asciminib 80 mgPost-treatment Period Switched From Imatinib to Asciminib 60 mg Combo
COVID-19Infections and infestations4/219/212/205/212/202/14——————
RashSkin and subcutaneous tissue disorders4/211/211/208/214/200/14——————
NauseaGastrointestinal disorders7/213/212/203/212/202/14——————
ArthralgiaMusculoskeletal and connective tissue disorders1/210/211/201/216/202/14——————
Abdominal pain upperGastrointestinal disorders2/211/210/202/215/200/14——————
Lipase increasedInvestigations4/214/213/202/215/202/14——————
DiarrhoeaGastrointestinal disorders5/213/213/201/210/202/14——————
Alanine aminotransferase increasedInvestigations2/211/210/205/212/200/14——————
MyalgiaMusculoskeletal and connective tissue disorders5/211/211/202/213/201/14——————
Blood creatine phosphokinase increasedInvestigations3/214/212/201/211/200/14——————

Baseline characteristics

Full Analysis set (FAs): The Full Analysis Set (FAS) comprised all subjects to whom study treatment was assigned by randomization for arms 1 to 4. Full Analysis Set Asciminib single agent cohort (FAS-ASAC) includes all subjects assigned to the ASAC.

Age, Customized
Age, Customized(Participants)Asciminib 40mg QD + Imatinib 400mg QDAsciminib 60mg QD + Imatinib 400mg QDImatinib 400mg QDNilotinib 300mg BIDAsciminib 80mg QDTotal
18 - <65 years181916191486
65 - <85 years3252618
Sex: Female, Male
Sex: Female, Male(Participants)Asciminib 40mg QD + Imatinib 400mg QDAsciminib 60mg QD + Imatinib 400mg QDImatinib 400mg QDNilotinib 300mg BIDAsciminib 80mg QDTotal
Female8556832
Male131616151272
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Asciminib 40mg QD + Imatinib 400mg QDAsciminib 60mg QD + Imatinib 400mg QDImatinib 400mg QDNilotinib 300mg BIDAsciminib 80mg QDTotal
White171519162087
Chinese000101
Indian010001
Korean121105
Missing - Asian310206
Missing - Overall021104
08

Study locations

30 sites
  • Georgia Regents University
    Augusta, Georgia 30912, United States
  • Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21205, United States
  • Novartis Investigative Site
    Vienna, 1140, Austria
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada
  • Novartis Investigative Site
    Brno, 625 00, Czechia
  • Novartis Investigative Site
    Copenhagen, DK-2100, Denmark
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Milan, MI 20162, Italy
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Krakow, 31 531, Poland
  • Novartis Investigative Site
    Warsaw, 00-791, Poland
  • Novartis Investigative Site
    Wroclaw, 50 367, Poland
  • Novartis Investigative Site
    Lisbon, 1099-023, Portugal
  • Novartis Investigative Site
    Porto, 4200-072, Portugal
  • Novartis Investigative Site
    Moscow, 125167, Russia
  • Novartis Investigative Site
    Moscow, 125284, Russia
  • Novartis Investigative Site
    Saint Petersburg, 191024, Russia
  • Novartis Investigative Site
    Saint Petersburg, 197341, Russia
  • Novartis Investigative Site
    Uijeongbu-si, Gyeonggi-do 11759, South Korea
  • Novartis Investigative Site
    Seoul, 06591, South Korea
  • Novartis Investigative Site
    Badalona, Barcelona 08916, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Seville, 41009, Spain
  • Novartis Investigative Site
    Valencia, 46026, Spain
  • Novartis Investigative Site
    Changhua, 50006, Taiwan
  • Novartis Investigative Site
    Taoyuan, 33305, Taiwan
  • Novartis Investigative Site
    Liverpool, CH63 4JY, United Kingdom
  • Novartis Investigative Site
    London, W12 0HS, United Kingdom
  • Novartis Investigative Site
    Oxford, OX3 7LE, United Kingdom
09

References and documents

Publications

  • Hughes TP, Saglio G, Geissler J, Kim DW, Lomaia E, Mayer J, Turkina A, Kapoor S, Cardoso AP, Nieman B, Quenet S, Cortes JE. Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study. J Hematol Oncol. 2024 Dec 18;17(1):125. doi: 10.1186/s13045-024-01642-6. PubMed 39696526 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Nov 2021, 35 months.

Results were first posted in Feb 2025, 3 years 3 months after primary completion. A results delay was requested in Oct 2022.

Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's 35 months is below that.

Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2018
First posted
Jul 6, 2018
StartActual
Nov 22, 2018
Primary completionActual
Nov 8, 2021
CompletionActual
Feb 26, 2025
Results delay requested
Oct 5, 2022
Results first posted
Feb 14, 2025
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03578367
Responsible party
Sponsor
First posted
Jul 6, 2018
Start date
Nov 22, 2018
Primary completion
Nov 8, 2021
Completion
Feb 26, 2025
Results posted
Feb 14, 2025
Last update
Apr 21, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Imatinib · Asciminib

Start the discussion